News and Trends 21 Sep 2022 NodThera reveals positive results for inflammasome inhibitors Biotech company NodThera has announced positive phase 1 clinical readouts for its first and second clinical candidates, NT-0796 and NT-0249. A phase 1 study has been completed for NT-0796, confirming brain penetration with excellent pharmacokinetic (PK) and pharmacodynamic (PD) profiles and for NT-0249, dosing of the phase 1 single ascending dose cohorts has been completed, […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Collaboration to explore gene therapy products for neurodegenerative disorders Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […] September 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 IRLAB’s partner Ipsen starts mesdopetam clinical studies IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […] September 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Researchers identify possible target for type of sporadic ALS Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Swiss biotech […] August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS Peer-review research published in Frontiers in Pharmacology supports the broad spectrum mechanism of action of Swedish biopharma company TikoMed’s ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis […] August 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Scientists unravel mystery behind neurodegenerative disease protein Scientists have unraveled the mystery behind the mechanism behind a type of protein that leads to a progressive nervous system disease. In a study, recently published in the journal Physical Chemistry Chemical Physics, the researchers say that the RNA-binding ‘fused in sarcoma’ (FUS) protein transitions between liquid and solid phases inside cells. The scientists from […] August 30, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA A drug to target a rare genetic form of a neurological disease that affects the nerve cells, leading to the loss of everyday functions, could be the first of its kind available if approved. The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Massachusetts-based Biogen Inc. for tofersen, an […] July 28, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders A neuroscience company targeting mitochondrial dysfunction has teamed up with an organization developing small molecule disease-modifying medicines for the treatment for chronic neurogenerative disorders. Domainex, an integrated medicines research services partner has been chosen by neuroscience company, NRG Therapeutics, and will be providing fully integrated lead optimization services including assay biology and medicinal computational chemistry. […] June 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Sponsored by WuXi AppTec 22 Sep 2021 Discovering New Therapeutic Targets for Alzheimer’s Disease Effective therapies for neurodegenerative diseases like Alzheimer’s are urgently needed. But developing new drugs is difficult, time-consuming, and expensive, with a high risk of failure. Strategic partnerships can help biotech companies manage costs and access the latest technologies to drive innovation and advance novel therapy ideas. A serious unmet medical need Finding treatments for neurodegenerative […] September 22, 2021 - 7 minutesmins - By Julia Kaiser Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2021 AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II results this week, raising tentative hopes for the field of treatments targeting the protein tau. For decades, the major culprit responsible for Alzheimer’s disease was suggested to be the buildup of a protein called amyloid-beta in the brain. Blocking this […] September 2, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2021 Danish Dementia Startup Launches Amid Maturing Nordic Biotech Scene Muna Therapeutics debuted with the Danish biotech sector’s biggest-ever Series A round earlier this month. This showcases the rapid growth taking place in the biotech industry in the Nordic region. Muna Therapeutics’ €62M ($73M) investment was co-led by the Danish investor Novo Holdings through its early-stage arm Novo Seeds. The startup was first set up […] July 20, 2021 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2021 FDA Approval of Biogen’s Drug Boosts European Alzheimer’s Space The FDA shocked many life sciences observers by greenlighting Biogen’s treatment candidate for Alzheimer’s last week. Yet, for much of the Alzheimer’s disease community on both sides of the Atlantic, the decision also brings cautious hope. Controversy recently erupted when the FDA conditionally granted accelerated approval to Biogen’s aducanumab, making it the first approved treatment […] June 17, 2021 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email